Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AndroGel Competitors Enter US After Perrigo’s Exclusivity Expires

Executive Summary

Following the expiry of Perrigo’s 180-day exclusivity for its generic version of AndroGel, firms including Lupin and Teva have launched their own generic testosterone 1.62% gels in the US.

You may also be interested in...

Perrigo Persists On Pepcid As Prescription Profit Plummets

Perrigo has won a US appeals court ruling on its generic version of Pepcid Complete. However, the company’s Prescription generics business saw a 15% drop in sales and a 28% decline in operating profit as the firm reported its 2018 results, ahead of plans to separate the Prescription unit from the company as it transitions to become a ‘self-care’ company.

Perrigo’s new leader backs generics plans

Perrigo’s newly-appointed president and chief executive officer, Murray Kessler, has backed the planned ‘separation’of the firm’s ‘Rx’ Prescription US generics operation, but has also praised the business’ potential, albeit in the face of a disappointing financial third quarter.

Shortlist Revealed Ahead Of October Awards

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts